Journal Article

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Wu, Yi-Long, Iyer, Shrividya, Mekhail, Tarek, Blackhall, Fiona, Felip, Enriqueta, Nakagawa, Kazuhiko, Paolini, Jolanda, Usari, Tiziana, Mok, Tony, Wilner, Keith D, Cappuzzo, Federico, Kim, Dong-Wan, Reisman, Arlene, Solomon, Benjamin J, Tursi, Jennifer

2014

Overview

The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater improvement in quality of life measures than standard chemotherapy in patients with ALK -positive lung cancer. Rearrangements of the anaplastic lymphoma kinase ( ALK ) gene are present in 3 to 5% of non–small-cell lung cancers (NSCLCs). 1 , 2 They define a distinct subgroup of NSCLC that typically occurs in younger patients who have never smoked or have a history of light smoking and that has adenocarcinoma histologic characteristics. 3 – 5 Crizotinib is an oral small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases. 6 In phase 1 and 2 studies, crizotinib treatment resulted in objective tumor responses in approximately 60% of patients with ALK -positive NSCLC and in progression-free survival of 7 to 10 months. 7 – 9 In . . .

• Publisher: Massachusetts Medical Society
• Subject: Adenocarcinoma - drug therapy / Adenocarcinoma - mortality / Adenocarcinoma/drug therapy/mortality / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use / Appetite loss / Biological and medical sciences / Biomedical research / Carboplatin / Carboplatin - administration & dosage / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung/drug therapy/mortality / Cardiovascular & respiratory systems / Chemotherapy / Cisplatin / Cisplatin - administration & dosage / Comparative studies / Diarrhea / Disease-Free Survival / Edema / Fatigue / Female / General aspects / Glutamates - administration & dosage / Guanine - administration & dosage / Guanine - analogs & derivatives / Guanine/administration & dosage/analogs & derivatives / Human health sciences / Humans / Inhibitor drugs / Intravenous administration / Kaplan-Meier Estimate / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - mortality / Lung Neoplasms/drug therapy/mortality / Lungs / Male / Medical sciences / Metastasis / Middle Aged / Multiple tumors. Solid tumors. Tumors in childhood (general aspects) / Nausea / Non-small cell lung carcinoma / Patients / Pemetrexed / Platinum / Pneumology / Protein Kinase Inhibitors - adverse effects / Protein Kinase Inhibitors - therapeutic use / Protein Kinase Inhibitors/adverse effects/therapeutic use / Pyrazoles - adverse effects / Pyrazoles - therapeutic use / Pyrazoles/adverse effects/therapeutic use / Pyridines - adverse effects / Pyridines - therapeutic use / Pyridines/adverse effects/therapeutic use / Quality of life / Receptor Protein-Tyrosine Kinases - antagonists & inhibitors / Sciences de la santé humaine / Systèmes cardiovasculaire & respiratoire / Targeted cancer therapy / Tumors / Tumors of the respiratory system and mediastinum / Vomiting